Open Access
Volume 9, Number 1, March 2019
Article Number 5
Number of page(s) 4
Published online 22 February 2019
  1. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 2017; 19(12): 991–1002 [CrossRef] [Google Scholar]
  2. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004; 80 Suppl 1: 3–7 [CrossRef] [Google Scholar]
  3. Oberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21 Suppl 7:vii72–80 [CrossRef] [Google Scholar]
  4. Hori T, Yasuda T, Suzuki K, Kanamori M, Kimura T. Skeletal metastasis of carcinoid tumors: Two case reports and review of the literature. Oncol Lett. 2012; 3(5): 1105–8 [CrossRef] [PubMed] [Google Scholar]
  5. Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, et al. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect. 2015; 4(1): 9–17 [CrossRef] [PubMed] [Google Scholar]
  6. Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, et al. Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med. 2003; 44(2): 184–91 [PubMed] [Google Scholar]
  7. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol. 2008; 26(18): 3063–72 [CrossRef] [PubMed] [Google Scholar]
  8. Arnold PM, Floyd HE, Anderson KK, Newell KL. Surgical management of carcinoid tumors metastatic to the spine: Report of three cases. Clin Neurol Neurosurg. 2010; 112(5): 443–5 [CrossRef] [PubMed] [Google Scholar]
  9. Padalkar P, Tow B. Predictors of survival in surgically treated patients of spinal metastasis. Indian J Orthop. 2011; 45(4): 307–13 [CrossRef] [PubMed] [Google Scholar]
  10. Delank KS, Wendtner C, Eich HT, Eysel P. The treatment of spinal metastases. Dtsch Arztebl Int. 2011; 108(5): 71–9; quiz 80 [PubMed] [Google Scholar]
  11. Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010; 40(4): 313–8 [CrossRef] [PubMed] [Google Scholar]
  12. Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001;92(5):1101–7 [CrossRef] [PubMed] [Google Scholar]
  13. Patta A, Fakih M. First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases. Anticancer Res. 2011; 31(3): 975–8 [PubMed] [Google Scholar]
  14. Lee J, Choi J, Choi C, Seong J. Role of radiotherapy for pancreato-biliary neuroendocrine tumors. Radiat Oncol J. 2013; 31(3): 12530 [Google Scholar]
  15. Iwata T, Ueno H, Itami J, Ito Y, Inaba K, Morizane C, et al. Efficacy of radiotherapy for primary tumor in patients with unresectable pancreatic neuroendocrine tumors. Jpn J Clin Oncol. 2017; 47(9): 826–31 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.